Ultragenyx Pharmaceutical Stock Price Target and Analyst Ratings (NASDAQ:RARE)

Analyst Price Target for RARE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$131.20

▲ +12.12% Upside Potential

This price target is based on 14 analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $131.20, with a high forecast of $186.00 and a low forecast of $66.00. The average price target represents a 12.12% upside from the last price of $117.02.

Buy

The current consensus among 14 investment analysts is to buy stock in Ultragenyx Pharmaceutical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
7 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

9/12/2019

0 strong buy ratings
6 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

12/11/2019

0 strong buy ratings
6 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

3/10/2020

0 strong buy ratings
8 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

6/8/2020

0 strong buy ratings
9 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

9/6/2020

0 strong buy ratings
10 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

12/5/2020

0 strong buy ratings
9 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

2/3/2021

0 strong buy ratings
8 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

3/5/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/1/2021	Stifel Nicolaus	Initiated Coverage	Buy	$179.00	High	i
2/16/2021	SVB Leerink	Boost Price Target	Outperform	$115.00 ➝ $178.00	Low	i
2/12/2021	Wedbush	Boost Price Target	Neutral	$113.00 ➝ $130.00	Low	i Rating by L. Chico at Wedbush
2/12/2021	Piper Sandler	Boost Price Target	Overweight	$165.00 ➝ $170.00	Low	i
2/12/2021	Barclays	Boost Price Target	Overweight	$176.00 ➝ $186.00	Low	i
2/12/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$165.00	Low	i
1/25/2021	Credit Suisse Group	Boost Price Target	Neutral	$64.00 ➝ $99.00	High	i
1/11/2021	Robert W. Baird	Boost Price Target	Outperform	$110.00 ➝ $165.00	Medium	i
1/11/2021	Barclays	Boost Price Target	Overweight	$121.00 ➝ $176.00	High	i
12/7/2020	Wedbush	Downgrade	Outperform ➝ Neutral	$105.00 ➝ $110.00	Medium	i Rating by L. Chico at Wedbush
11/24/2020	Evercore ISI	Reiterated Rating	In-Line	$110.00	High	i
11/12/2020	Bank of America	Downgrade	Buy ➝ Neutral	$104.00 ➝ $126.00	High	i
10/29/2020	Canaccord Genuity	Boost Price Target	Buy	$92.00 ➝ $105.00	High	i
10/28/2020	Truist	Boost Price Target		$88.00 ➝ $110.00	High	i
10/28/2020	Wedbush	Boost Price Target	Outperform	$97.00 ➝ $105.00	Low	i
10/28/2020	Morgan Stanley	Boost Price Target	Overweight	$89.00 ➝ $91.00	Low	i
10/28/2020	Barclays	Boost Price Target	Overweight	$99.00 ➝ $121.00	Medium	i
10/28/2020	SVB Leerink	Boost Price Target	Outperform	$110.00 ➝ $115.00	Medium	i
10/27/2020	Piper Sandler	Boost Price Target	Overweight	$83.00 ➝ $108.00	Medium	i
10/15/2020	Bank of America	Boost Price Target	Buy	$93.00 ➝ $107.00	Medium	i
10/13/2020	Morgan Stanley	Boost Price Target	Overweight	$87.00 ➝ $89.00	Medium	i
8/26/2020	Canaccord Genuity	Boost Price Target	Buy	$91.00 ➝ $92.00	High	i
7/31/2020	Credit Suisse Group	Reiterated Rating	Hold	$64.00	Low	i Rating by Martin Auster at Credit Suisse Group AG
7/31/2020	Morgan Stanley	Lower Price Target	Overweight	$88.00 ➝ $87.00	High	i
7/31/2020	Barclays	Boost Price Target	Overweight	$87.00 ➝ $99.00	Low	i
7/28/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy	$84.00	High	i
7/15/2020	Morgan Stanley	Boost Price Target	Overweight	$83.00 ➝ $88.00	Low	i
7/2/2020	Canaccord Genuity	Boost Price Target	Buy	$85.00 ➝ $91.00	Medium	i
7/1/2020	SunTrust Banks	Boost Price Target		$82.00 ➝ $88.00	Medium	i Rating by Joon Lee at SunTrust Banks, Inc.
7/1/2020	Credit Suisse Group	Boost Price Target	Neutral	$60.00 ➝ $64.00	High	i
7/1/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$76.00 ➝ $84.00	High	i
7/1/2020	Wedbush	Boost Price Target	Hold ➝ Outperform	$83.00 ➝ $91.00	High	i
7/1/2020	Morgan Stanley	Boost Price Target	Overweight	$79.00 ➝ $83.00	High	i
7/1/2020	Robert W. Baird	Boost Price Target	Outperform	$75.00 ➝ $90.00	High	i Rating by Michael Ulz at Robert W. Baird
6/30/2020	Piper Sandler	Boost Price Target	Overweight	$70.00 ➝ $83.00	High	i
6/19/2020	SunTrust Banks	Boost Price Target	Buy	$80.00 ➝ $82.00	High	i Rating by Joon Lee at SunTrust Banks, Inc.
6/19/2020	Wedbush	Boost Price Target	Outperform	$73.00 ➝ $83.00	High	i
6/19/2020	Canaccord Genuity	Boost Price Target	Buy	$75.00 ➝ $85.00	High	i
5/18/2020	Stifel Nicolaus	Boost Price Target	Positive ➝ Buy	$70.00 ➝ $82.00	High	i
5/8/2020	Citigroup	Boost Price Target	Neutral	$53.00 ➝ $66.00	Low	i
4/1/2020	Robert W. Baird	Reiterated Rating	Buy	$75.00	High	i Rating by Michael Ulz at Robert W. Baird
2/18/2020	Evercore ISI	Reiterated Rating	Buy		Low	i
2/16/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy	$76.00	Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
2/14/2020	Wedbush	Boost Price Target	Outperform	$71.00 ➝ $75.00	High	i
2/14/2020	Cowen	Reiterated Rating	Buy	$75.00	High	i
1/17/2020	Morgan Stanley	Boost Price Target	Overweight	$73.00 ➝ $77.00	Low	i
1/10/2020	SunTrust Banks	Reiterated Rating	Buy	$75.00 ➝ $80.00	High	i
1/2/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		High	i
12/18/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$70.00	High	i Rating by Christopher Raymond at Piper Jaffray Companies
12/18/2019	Cowen	Reiterated Rating	Buy	$59.00	High	i
12/17/2019	Morgan Stanley	Lower Price Target	Overweight	$76.00 ➝ $73.00	Medium	i
11/6/2019	Morgan Stanley	Lower Price Target	Overweight	$79.00 ➝ $76.00	High	i Rating by Jeffrey Hung at Morgan Stanley
11/6/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$75.00	High	i Rating by Cory Kasimov at JPMorgan Chase & Co.
11/5/2019	Cowen	Reiterated Rating	Buy	$62.00	High	i
9/4/2019	Piper Jaffray Companies	Set Price Target	Buy	$75.00	Low	i Rating by Christopher Raymond at Piper Jaffray Companies
9/4/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
9/4/2019	SVB Leerink	Reiterated Rating	Outperform ➝ Positive	$80.00 ➝ $85.00	High	i
8/15/2019	Wedbush	Reiterated Rating	Buy	$75.00	High	i Rating by L. Chico at Wedbush
8/15/2019	Cowen	Reiterated Rating	Buy		High	i
8/5/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$75.00	Medium	i
8/4/2019	Barclays	Reiterated Rating	Buy	$87.00	Medium	i
8/2/2019	Morgan Stanley	Lower Price Target	Overweight	$83.00 ➝ $79.00	High	i Rating by Jeffrey Hung at Morgan Stanley
8/2/2019	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$75.00	High	i Rating by L. Chico at Wedbush
6/17/2019	Morgan Stanley	Set Price Target	Buy	$83.00	Low	i Rating by Jeffrey Hung at Morgan Stanley
5/9/2019	Barclays	Reiterated Rating	Buy		Low	i
5/7/2019	Wedbush	Reiterated Rating	Outperform	$88.00 ➝ $77.00	High	i
3/27/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$68.00 ➝ $83.00	Medium	i Rating by Jeffrey Hung at Morgan Stanley
2/26/2019	Cowen	Reiterated Rating	Buy	$69.00	High	i
2/22/2019	Raymond James	Reiterated Rating	Outperform ➝ Outperform	$80.00	Low	i Rating by Laura Chico at Raymond James
2/21/2019	Citigroup	Boost Price Target	Neutral ➝ Neutral	$54.00 ➝ $62.00	High	i
2/20/2019	Credit Suisse Group	Reiterated Rating	Hold	$59.00	High	i Rating by Martin Auster at Credit Suisse Group AG
1/23/2019	SunTrust Banks	Boost Price Target	Buy	$71.00	High	i
1/7/2019	Wedbush	Reiterated Rating	Outperform	$88.00	Medium	i
1/7/2019	Cowen	Reiterated Rating	Buy		Medium	i
1/4/2019	Credit Suisse Group	Set Price Target	Hold	$59.00	Medium	i Rating by Martin Auster at Credit Suisse Group AG
1/2/2019	Raymond James	Downgrade	Outperform ➝ Market Perform		Medium	i Rating by Laura Chico at Raymond James
11/15/2018	Credit Suisse Group	Set Price Target	Hold	$59.00	High	i Rating by Martin Auster at Credit Suisse Group AG
11/14/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium	i Rating by Cory Kasimov at JPMorgan Chase & Co.
11/8/2018	Citigroup	Upgrade	Sell ➝ Neutral	$46.00 ➝ $54.00	N/A	i
11/7/2018	Canaccord Genuity	Lower Price Target	Buy	$90.00 ➝ $75.00	Low	i
11/6/2018	Raymond James	Boost Price Target	Outperform ➝ Buy	$53.00 ➝ $57.00	Medium	i Rating by Laura Chico at Raymond James
10/29/2018	Wedbush	Lower Price Target	Outperform ➝ Outperform	$90.00 ➝ $88.00	High	i
10/29/2018	Citigroup	Lower Price Target	Sell ➝ Sell	$49.00 ➝ $46.00	High	i
10/29/2018	Morgan Stanley	Set Price Target	Hold	$92.00 ➝ $70.00	High	i Rating by Jeffrey Hung at Morgan Stanley
10/29/2018	Credit Suisse Group	Lower Price Target	Neutral ➝ Hold	$78.00 ➝ $59.00	High	i Rating by Martin Auster at Credit Suisse Group AG
10/29/2018	SunTrust Banks	Lower Price Target	Buy ➝ Buy	$83.00 ➝ $54.00	Medium	i
10/27/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$68.00	Medium	i Rating by Cory Kasimov at JPMorgan Chase & Co.
10/26/2018	Raymond James	Set Price Target	Buy	$70.00	Low	i Rating by Laura Chico at Raymond James
10/26/2018	Piper Jaffray Companies	Lower Price Target	Overweight	$70.00	High	i
10/7/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy	$86.00	Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
9/11/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$72.00 ➝ $94.00	Low	i
9/10/2018	Morgan Stanley	Reiterated Rating	Equal ➝ Equal Weight	$92.00	Low	i
9/2/2018	JMP Securities	Reiterated Rating	Buy	$94.00	Medium	i
8/30/2018	Wedbush	Boost Price Target	Outperform ➝ Outperform	$80.00 ➝ $90.00	Medium	i
8/29/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium	i Rating by Cory Kasimov at JPMorgan Chase & Co.
8/20/2018	SunTrust Banks	Boost Price Target	Buy ➝ Positive	$83.00	Low	i
8/6/2018	Wedbush	Boost Price Target	Outperform ➝ Outperform	$71.00 ➝ $80.00	High	i
8/3/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$80.00 ➝ $90.00	High	i
8/3/2018	Robert W. Baird	Reiterated Rating	Buy	$95.00	High	i
8/3/2018	Barclays	Reiterated Rating	Overweight ➝ Overweight	$74.00 ➝ $92.00	High	i
8/3/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$85.00	High	i
7/17/2018	SVB Leerink	Boost Price Target	Outperform ➝ Outperform	$68.00 ➝ $95.00	Low	i
6/21/2018	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$67.00 ➝ $80.00	High	i
5/11/2018	Barclays	Upgrade	Equal Weight ➝ Overweight	$62.00 ➝ $74.00	High	i
5/10/2018	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$63.00	Medium	i
4/18/2018	Cowen	Reiterated Rating	Buy		Medium	i
4/18/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$74.00 ➝ $77.00	High	i
4/18/2018	Wedbush	Reiterated Rating	Outperform ➝ Positive	$64.00 ➝ $71.00	High	i
4/18/2018	JMP Securities	Boost Price Target	Outperform	$70.00 ➝ $74.00	High	i
4/18/2018	SunTrust Banks	Upgrade	Hold ➝ Buy	$41.67 ➝ $55.00	Low	i
4/17/2018	Bank of America	Boost Price Target		$61.00 ➝ $72.00	Low	i
3/22/2018	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Overweight	$67.00	Medium	i
2/23/2018	Robert W. Baird	Reiterated Rating	Buy	$70.00	Medium	i
2/21/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $61.00	High	i
2/21/2018	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$57.00 ➝ $60.00	High	i
2/21/2018	JPMorgan Chase & Co.	Reiterated Rating	Market Outperform ➝ Overweight	$68.00 ➝ $66.00	High	i
2/21/2018	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$85.00 ➝ $74.00	High	i
1/22/2018	Evercore ISI	Upgrade	In-Line ➝ Outperform		High	i
1/17/2018	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$67.00	Low	i
12/15/2017	Raymond James	Reiterated Rating	Buy		Low	i Rating by Laura Chico at Raymond James
12/5/2017	Raymond James	Reiterated Rating	Buy		Medium	i Rating by Laura Chico at Raymond James
12/5/2017	Canaccord Genuity	Set Price Target	Buy	$80.00	Medium	i Rating by Arlinda Lee at Canaccord Genuity
12/5/2017	Barclays	Boost Price Target	Equal Weight ➝ Equal Weight	$60.00 ➝ $62.00	High	i
12/4/2017	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$58.00 ➝ $72.00	High	i Rating by Maury Raycroft at Jefferies Financial Group Inc.
11/16/2017	Canaccord Genuity	Set Price Target	Buy	$83.00 ➝ $80.00	N/A	i Rating by Arlinda Lee at Canaccord Genuity
11/15/2017	Cowen	Reiterated Rating	Buy		N/A	i
11/5/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy	$76.00	N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
11/3/2017	Robert W. Baird	Lower Price Target	Outperform	$85.00 ➝ $80.00	N/A	i
10/6/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$69.00 ➝ $71.00	N/A	i
9/19/2017	Robert W. Baird	Reiterated Rating	Buy		Low	i
9/14/2017	Wedbush	Upgrade	Neutral ➝ Outperform	$62.00	High	i Rating by D. Nierengarten at Wedbush
9/12/2017	Canaccord Genuity	Reiterated Rating	Buy		Low	i Rating by Arlinda Lee at Canaccord Genuity
9/6/2017	Barclays	Initiated Coverage	Equal Weight	$60.00	High	i
8/23/2017	Jefferies Financial Group	Set Price Target	Hold	$62.00	Low	i Rating by Maury Raycroft at Jefferies Financial Group Inc.
8/23/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$87.00 ➝ $76.00	Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
8/23/2017	JMP Securities	Lower Price Target	Market Outperform	$90.00 ➝ $80.00	Low	i
8/23/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$80.00 ➝ $69.00	High	i
8/23/2017	Stifel Nicolaus	Reiterated Rating	Buy	$95.00 ➝ $85.00	High	i
8/23/2017	SVB Leerink	Reiterated Rating	Outperform	$89.00 ➝ $83.00	High	i
8/23/2017	Cowen	Reiterated Rating	Outperform		High	i
8/23/2017	SunTrust Banks	Downgrade	Buy ➝ Hold	$105.00 ➝ $55.00	High	i
8/22/2017	Canaccord Genuity	Reiterated Rating	Buy	$98.00 ➝ $83.00	High	i Rating by Arlinda Lee at Canaccord Genuity
8/16/2017	Evercore ISI	Initiated Coverage	In ➝ In-Line	$63.00	High	i
8/8/2017	HC Wainwright	Reiterated Rating	Neutral ➝ Neutral	$72.00 ➝ $75.00	Low	i Rating by C. Werther at HC Wainwright
7/28/2017	Canaccord Genuity	Set Price Target	Buy	$98.00	Low	i Rating by Arlinda Lee at Canaccord Genuity
7/27/2017	Sanford C. Bernstein	Initiated Coverage	Market Perform	$72.00	High	i
7/14/2017	Jefferies Financial Group	Reiterated Rating	Hold	$68.00	High	i
6/30/2017	Stifel Nicolaus	Reiterated Rating	Buy	$111.00	Low	i
6/29/2017	Cowen	Reiterated Rating	Outperform		Low	i
5/8/2017	Canaccord Genuity	Reiterated Rating	Buy		Low	i Rating by Arlinda Lee at Canaccord Genuity
5/8/2017	Morgan Stanley	Lower Price Target	Equal Weight	$84.00 ➝ $79.00	Low	i
5/8/2017	Jefferies Financial Group	Boost Price Target	Hold	$66.00 ➝ $68.00	Low	i Rating by Gena Wang at Jefferies Financial Group Inc.
4/19/2017	Robert W. Baird	Reiterated Rating	Outperform	$90.00	Medium	i
4/19/2017	Cowen	Reiterated Rating	Outperform		Medium	i
4/19/2017	SunTrust Banks	Boost Price Target	Buy	$100.00 ➝ $105.00	Medium	i
4/19/2017	Canaccord Genuity	Reiterated Rating	Buy	$100.00	High	i Rating by Arlinda Lee at Canaccord Genuity
4/19/2017	Wedbush	Downgrade	Outperform ➝ Neutral	$80.00 ➝ $75.00	High	i Rating by D. Nierengarten at Wedbush
4/19/2017	HC Wainwright	Downgrade	Buy ➝ Neutral	$88.00 ➝ $72.00	High	i Rating by C. Werther at HC Wainwright
4/6/2017	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$109.00 ➝ $66.00	High	i Rating by Gena Wang at Jefferies Financial Group Inc.
3/23/2017	HC Wainwright	Reiterated Rating	Buy		High	i Rating by C. Werther at HC Wainwright
3/23/2017	Cowen	Reiterated Rating	Buy		High	i
3/23/2017	Canaccord Genuity	Reiterated Rating	Buy	$100.00	Medium	i Rating by Arlinda Lee at Canaccord Genuity
3/23/2017	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Neutral		High	i Rating by Steven Breazzano at Piper Jaffray Companies
3/23/2017	Wedbush	Lower Price Target	Buy	$88.00 ➝ $80.00	High	i Rating by D. Nierengarten at Wedbush
3/22/2017	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$96.00 ➝ $70.00	High	i
2/17/2017	Cowen	Reiterated Rating	Buy		N/A	i
2/17/2017	Wedbush	Initiated Coverage	Outperform	$88.00	N/A	i
2/17/2017	Jefferies Financial Group	Reiterated Rating	Buy	$109.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
11/30/2016	Citigroup	Downgrade	Neutral ➝ Sell		N/A	i Rating by Yigal Nochomovitz at Citigroup Inc.
11/30/2016	Wedbush	Reiterated Rating	Outperform	$92.00	N/A	i Rating by Heather Behanna at Wedbush
11/30/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$96.00	N/A	i Rating by steven breazzano at Piper Jaffray Companies
11/14/2016	Jefferies Financial Group	Set Price Target	Buy	$109.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
11/14/2016	SVB Leerink	Reiterated Rating	Outperform	$94.00 ➝ $90.00	N/A	i Rating by Joseph Schwartz at SVB Leerink LLC
11/14/2016	Citigroup	Downgrade	Neutral ➝ Sell	$66.00 ➝ $64.00	N/A	i
11/11/2016	Canaccord Genuity	Set Price Target	Buy	$103.00	N/A	i Rating by Arlinda Lee at Canaccord Genuity
11/9/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy	$106.00	N/A	i Rating by cory kasimov at JPMorgan Chase & Co.
11/8/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$79.00	N/A	i Rating by steven breazzano at Piper Jaffray Companies
11/8/2016	Wedbush	Reiterated Rating	Outperform	$92.00	N/A	i Rating by Heather Behanna at Wedbush
10/21/2016	Canaccord Genuity	Set Price Target	Buy	$120.00	N/A	i Rating by Arlinda Lee at Canaccord Genuity
9/25/2016	HC Wainwright	Reiterated Rating	Buy	$102.00 ➝ $109.00	N/A	i
9/20/2016	Canaccord Genuity	Set Price Target	Buy	$120.00	N/A	i Rating by arlinda lee at Canaccord Genuity
9/20/2016	SVB Leerink	Reiterated Rating	Outperform	$85.00 ➝ $94.00	N/A	i Rating by Joseph Schwartz at SVB Leerink LLC
9/19/2016	Wedbush	Reiterated Rating	Outperform	$92.00	N/A	i Rating by Heather Behanna at Wedbush
9/18/2016	Jefferies Financial Group	Set Price Target	Buy	$109.00	N/A	i Rating by gena wang at Jefferies Financial Group Inc.
9/14/2016	Credit Suisse Group	Reiterated Rating	Buy	$101.00	N/A	i Rating by Kennen MacKay at Credit Suisse Group AG
9/12/2016	Jefferies Financial Group	Set Price Target	Buy	$109.00	N/A	i Rating by gena wang at Jefferies Financial Group Inc.
8/25/2016	SVB Leerink	Reiterated Rating	Buy	$86.00	N/A	i Rating by Joseph Schwartz at SVB Leerink LLC
8/9/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Eric Schmidt at Cowen Inc
8/9/2016	Piper Jaffray Companies	Set Price Target	Buy	$70.00 ➝ $82.00	N/A	i Rating by steven breazzano at Piper Jaffray Companies
8/9/2016	Credit Suisse Group	Reiterated Rating	Buy	$101.00	N/A	i Rating by Kennen MacKay at Credit Suisse Group AG
8/9/2016	Wedbush	Reiterated Rating	Outperform	$92.00	N/A	i Rating by Heather Behanna at Wedbush
8/8/2016	JPMorgan Chase & Co.	Set Price Target	Buy	$110.00	N/A	i Rating by cory kasimov at JPMorgan Chase & Co.
8/1/2016	Jefferies Financial Group	Set Price Target	Buy	$109.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
7/18/2016	Robert W. Baird	Reiterated Rating	Outperform	$85.00	N/A	i
7/17/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
7/17/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$70.00	N/A	i
7/15/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Eric Schmidt at Cowen Inc
7/15/2016	SVB Leerink	Reiterated Rating	Buy	$85.00	N/A	i Rating by Joseph Schwartz at SVB Leerink LLC
7/15/2016	Canaccord Genuity	Reiterated Rating	Buy	$120.00	N/A	i Rating by Arlinda Lee at Canaccord Genuity
7/12/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i Rating by Kennen MacKay at Credit Suisse Group AG
7/7/2016	Piper Jaffray Companies	Initiated Coverage	Overweight	$70.00	N/A	i
6/28/2016	Wedbush	Reiterated Rating	Outperform	$92.00	N/A	i Rating by Heather Behanna at Wedbush
6/28/2016	Bank of America	Initiated Coverage	Buy	$72.00	N/A	i
6/16/2016	Canaccord Genuity	Reiterated Rating	Buy	$120.00	N/A	i Rating by Arlinda Lee at Canaccord Genuity
6/16/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Joseph Schwartz at SVB Leerink LLC
6/10/2016	SVB Leerink	Reiterated Rating	Outperform	$80.00 ➝ $85.00	N/A	i Rating by Joseph Schwartz at SVB Leerink LLC
6/8/2016	Morgan Stanley	Reiterated Rating	Hold		N/A	i Rating by Matthew Harrison at Morgan Stanley
6/8/2016	JMP Securities	Reiterated Rating	Buy	$80.00 ➝ $84.00	N/A	i
6/8/2016	Jefferies Financial Group	Reiterated Rating	Buy	$109.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
5/25/2016	Credit Suisse Group	Reiterated Rating	Buy	$101.00	N/A	i Rating by Kennen MacKay at Credit Suisse Group AG
5/10/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i Rating by Kennen MacKay at Credit Suisse Group AG
5/10/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by Arlinda Lee at Canaccord Genuity
5/10/2016	SVB Leerink	Reiterated Rating	Buy	$80.00	N/A	i Rating by Joseph Schwartz at SVB Leerink LLC
5/10/2016	Jefferies Financial Group	Reiterated Rating	Buy	$109.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
5/10/2016	Wedbush	Reiterated Rating	Outperform	$99.00 ➝ $92.00	N/A	i
4/4/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by Arlinda Lee at Canaccord Genuity
3/7/2016	Robert W. Baird	Initiated Coverage	Outperform	$85.00	N/A	i

(Data available from 3/5/2016 forward)

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.

Today's Range

Now: $117.02

$110.78

$119.16

50 Day Range

MA: $145.21

$125.30

$167.73

52 Week Range

Now: $117.02

$31.99

$179.65

Volume

29,360 shs

Average Volume

466,050 shs

Market Capitalization

$7.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Ultragenyx Pharmaceutical?

The following equities research analysts have issued reports on Ultragenyx Pharmaceutical in the last twelve months: Bank of America Co., Barclays PLC, Canaccord Genuity, Citigroup Inc., Credit Suisse Group AG, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Robert W. Baird, Stifel Nicolaus, SunTrust Banks, Inc., SVB Leerink LLC, TheStreet, Truist, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for RARE.

What is the current price target for Ultragenyx Pharmaceutical?

15 Wall Street analysts have set twelve-month price targets for Ultragenyx Pharmaceutical in the last year. Their average twelve-month price target is $131.20, suggesting a possible upside of 10.6%. Barclays PLC has the highest price target set, predicting RARE will reach $186.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $66.00 for Ultragenyx Pharmaceutical in the next year.
View the latest price targets for RARE.

What is the current consensus analyst rating for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical currently has 6 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RARE will outperform the market and that investors should add to their positions of Ultragenyx Pharmaceutical.
View the latest ratings for RARE.

What other companies compete with Ultragenyx Pharmaceutical?

Other companies that are similar to Ultragenyx Pharmaceutical include Shiseido, Astellas Pharma, Takeda Pharmaceutical, BeiGene, MERCK Kommanditgesellschaft auf Aktien, Genmab A/S, Horizon Therapeutics Public, UCB, Genmab A/S, Catalent, Royalty Pharma, Alnylam Pharmaceuticals, Ono Pharmaceutical, CureVac and Elanco Animal Health.

How do I contact Ultragenyx Pharmaceutical's investor relations team?

Ultragenyx Pharmaceutical's physical mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company's listed phone number is 415-483-8800 and its investor relations email address is [email protected] The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price Target and Predictions

Analyst Price Target for RARE

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Ultragenyx Pharmaceutical?

What is the current price target for Ultragenyx Pharmaceutical?

What is the current consensus analyst rating for Ultragenyx Pharmaceutical?

What other companies compete with Ultragenyx Pharmaceutical?

How do I contact Ultragenyx Pharmaceutical's investor relations team?